Clinical Trial Update: Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab plus relatlimab with gemcitabine/cisplatin as first-line treatment for advanced biliary tract cancer; the study status is NOT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemzar (gemcitabine)
• OPDIVO (nivolumab)
• Relatlimab (relatlimab)

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Advanced Biliary Tract Cancer(BTC) | Phase 2 | Status: NOT_YET_RECRUITING